Tag Archives: ALXN

Alexion, Vertex Steal Mo Stanley’s Eyes From Gilead

Morgan Stanley analyst Matthew Harrison downgraded Gilead Sciences (GILD) while upgrading Alexion Pharmaceuticals (ALXN) and Vertex Pharmaceuticals (VRTX), based on where he sees near-term catalysts in the current volatile market. Harrison maintained his price target of 127 on Gilead, but lowered his rating to equal-weight from overweight based on “relative attractiveness” to the other two stocks. Harrison wrote in a research note that while it’s

Alexion Facing Big Costs, Guidance Disappoints

Rare-disease specialist (ALXN) beat Q2 estimates Thursday morning, but its stock dropped as its guidance fell short of expectations amid some big costs. Alexion said that its earnings rose 29% over the year-earlier quarter to $1.44 a share, beating analysts’ consensus by 6 cents, according to Thomson Reuters. Revenue climbed 24% to $636 million, about $8 million above consensus. Alexion lifted and tightened its full-year revenue outlook slightly,

Alnylam Reports Data on Potential Alexion Rival Drug

Biotech Alnylam Pharmaceuticals (ALNY) reported positive data Friday on a rare-disease drug candidate and potential competitor to Alexion’s (ALXN) blockbuster Soliris. The market was underwhelmed, however, and Alnylam stock was down more than 3% in midday trading. Alnylam reported initial results from a phase 1/2 trial of ALN-CC5, a drug it’s developing with Sanofi’s (SNY) Genzyme division that targets complement component C5. Complements are